1DCCT Research Group. Diabetes 1997; 46:271 - 286. Ward et al. NZ Med J 1990;103 : 339 - 341.
2Tth ADVANCE collaborative group. Intensive blood glueose control and vascular outcomes in patients with type 2 diabetes. N Engl Med 2008 ;358:2545 - 2559.
5Garber AJ, Wahlen J , wahl T , et al. Attainment of glyeaemic goals in type 2 diabetes with once -, twice -, thrice - daily dosing with biphasic insulin aspart 70/30 (The 1 -2 -3 study). Diabetes Obes Metab 2006;8(1) :58 -66.
3Dunn CJ, Plosker GL, Keating GM,et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs, 2003,63 : 1743-1778.
4Schaepelynck-Belicar P, Vague P, Simonin G, et al. Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS) . Diabetes Metab, 2003,29:608-612.
5Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther, 2004,26:889-901.
6Riddle MC, Rosenstock J, Gerich J. The treat-to-target thai:randomized addition of glarglne or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003,26:3080-3086.
7Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care, 2000,23:45-50.
